BioNTech’s (BNTX) “Buy” Rating Reaffirmed at Truist Financial

BioNTech (NASDAQ:BNTXGet Free Report)‘s stock had its “buy” rating reissued by equities researchers at Truist Financial in a research note issued to investors on Tuesday,Benzinga reports. They currently have a $155.00 price objective on the stock, up from their previous price objective of $151.00. Truist Financial’s price target would suggest a potential upside of 39.46% from the company’s current price.

Several other research analysts also recently commented on the company. JPMorgan Chase & Co. reduced their target price on BioNTech from $120.00 to $116.00 and set a “neutral” rating on the stock in a report on Thursday, May 22nd. Wall Street Zen downgraded BioNTech from a “hold” rating to a “sell” rating in a report on Friday, May 30th. The Goldman Sachs Group initiated coverage on BioNTech in a report on Thursday, May 29th. They issued a “neutral” rating and a $110.00 target price on the stock. Citigroup reissued a “buy” rating and issued a $140.00 target price (down from $145.00) on shares of BioNTech in a report on Tuesday, May 6th. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and set a $171.44 price objective on shares of BioNTech in a report on Tuesday, March 11th. One investment analyst has rated the stock with a sell rating, four have given a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $139.14.

Read Our Latest Analysis on BNTX

BioNTech Stock Down 3.9%

NASDAQ BNTX opened at $111.14 on Tuesday. The company has a current ratio of 7.33, a quick ratio of 7.21 and a debt-to-equity ratio of 0.01. The stock’s 50 day moving average is $98.51 and its two-hundred day moving average is $108.28. The company has a market capitalization of $26.72 billion, a price-to-earnings ratio of -52.92 and a beta of 1.29. BioNTech has a 1-year low of $76.53 and a 1-year high of $131.49.

BioNTech (NASDAQ:BNTXGet Free Report) last released its quarterly earnings data on Monday, March 10th. The company reported $1.08 earnings per share for the quarter, beating analysts’ consensus estimates of $0.38 by $0.70. The company had revenue of $1.19 billion for the quarter, compared to the consensus estimate of $1.24 billion. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The company’s quarterly revenue was down 19.5% on a year-over-year basis. During the same period in the previous year, the business earned $1.90 earnings per share. Equities analysts forecast that BioNTech will post -3.88 earnings per share for the current fiscal year.

Institutional Trading of BioNTech

Large investors have recently made changes to their positions in the company. Banque Cantonale Vaudoise bought a new stake in shares of BioNTech in the 1st quarter valued at $36,000. Jones Financial Companies Lllp boosted its stake in shares of BioNTech by 110.3% during the 4th quarter. Jones Financial Companies Lllp now owns 469 shares of the company’s stock worth $53,000 after buying an additional 246 shares during the last quarter. Banque Transatlantique SA acquired a new position in shares of BioNTech during the 1st quarter worth about $80,000. Quintet Private Bank Europe S.A. lifted its stake in BioNTech by 823.5% in the 4th quarter. Quintet Private Bank Europe S.A. now owns 785 shares of the company’s stock valued at $88,000 after purchasing an additional 700 shares during the last quarter. Finally, Allianz SE acquired a new stake in BioNTech in the 4th quarter valued at about $90,000. Institutional investors own 15.52% of the company’s stock.

BioNTech Company Profile

(Get Free Report)

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.

See Also

Analyst Recommendations for BioNTech (NASDAQ:BNTX)

Receive News & Ratings for BioNTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNTech and related companies with MarketBeat.com's FREE daily email newsletter.